Treatment of relapsed acute myeloid leukaemia after allogeneic bone marrow transplantation with combination chemotherapy of cytarabine, idarubicin plus etoposide and subsequent donor leukocyte infusion: a prospective study

被引：0
|
作者：
Choi, SJ [1 ]
Lee, JH [1 ]
Lee, JH [1 ]
Kim, S [1 ]
Seol, M [1 ]
Lee, YS [1 ]
Lee, JS [1 ]
Kim, WK [1 ]
Lee, KH [1 ]
机构：
[1] Asan Med Ctr, Seoul, South Korea
来源：
BONE MARROW TRANSPLANTATION | 2004年 / 33卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S232 / S233
页数：2
相关论文
共 50 条
  • [21] Acute myeloid leukaemia of donor cell origin developing 5 years after allogeneic bone marrow transplantation for chronic myeloid leukaemia
    L Gopcsa
    A Barta
    A Banyai
    M Konya
    L Pajor
    J Földi
    K Paloczi
    Bone Marrow Transplantation, 2002, 29 : 449 - 452
  • [22] Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: Indications and dose escalation
    Shiobara, S
    Nakao, S
    Ueda, M
    Yamazaki, H
    Takahashi, S
    Asano, S
    Yabe, H
    Kato, S
    Imoto, S
    Maruta, A
    Yoshida, T
    Gondo, H
    Morishima, Y
    Kodera, Y
    THERAPEUTIC APHERESIS, 2001, 5 (01): : 40 - 45
  • [23] Efficacy of donor lymphocyte infusion following cytoreductive chemotherapy for relapsed acute leukaemia after allogeneic stem cell transplantation
    Kim, DY
    Lee, KW
    Yun, T
    Kim, SI
    Park, SR
    Paik, JY
    Choi, IS
    Oh, DY
    Yoon, SS
    Lee, JS
    Park, S
    Kim, BK
    BONE MARROW TRANSPLANTATION, 2004, 33 : S99 - S99
  • [24] Combination chemotherapy and donor lymphocyte infusion for treatment of aggressive hematologic malignancies in relapse after allogeneic bone marrow transplantation.
    Mookerjee, B
    Couzi, R
    Seber, A
    Miller, C
    Noga, S
    Douglas, T
    Altomonte, V
    Gore, S
    Jones, R
    Vogelsang, G
    Fuchs, E
    CLINICAL CANCER RESEARCH, 1999, 5 : 3734S - 3734S
  • [25] Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation
    Collins, RH
    Shpilberg, O
    Drobyski, WR
    Porter, DL
    Giralt, S
    Champlin, R
    Goodman, SA
    Wolff, SN
    Hu, W
    Verfaillie, C
    List, A
    Dalton, W
    Ognoskie, N
    Chetrit, A
    Antin, JH
    Nemunaitis, J
    JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) : 433 - 444
  • [26] Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation
    Lokhorst, HM
    Schattenberg, A
    Cornelissen, JJ
    Thomas, LLM
    Verdonck, LF
    BLOOD, 1997, 90 (10) : 4206 - 4211
  • [27] Impact of donor lymphocyte infusion for hematological malignancy relapsed after allogeneic bone marrow transplantation
    Zeder, K
    Waller, EK
    Redei, I
    Connaghan, DG
    Fleming, WH
    Geller, RB
    Heffner, LT
    Hillyer, CD
    Holden, J
    Holland, K
    Jones, W
    Mccollum, J
    Mogul, M
    Phillips, C
    Rodey, G
    Wingard, JR
    Winton, E
    Yeager, AM
    Devine, S
    CANCER RESEARCH THERAPY & CONTROL, 1998, 5 (04): : 221 - 228
  • [28] Donor leukocyte infusions (DLI) for the treatment of relapsed hematological malignancies after allogeneic elutriated bone marrow transplantation (BMT).
    Seber, A
    Noga, SJ
    Harris, D
    Hattenburg, C
    Fuchs, EJ
    BLOOD, 1996, 88 (10) : 1030 - 1030
  • [29] Donor mononuclear cells infusion and alfa interferon administration in relapsed chronic myeloid leukemia patients after allogeneic bone marrow transplantation
    Gurman, G
    Koc, H
    Akan, H
    Ilhan, O
    Ozcan, M
    Arslan, O
    Sunguroglu, A
    Konuk, N
    Beksac, M
    Uysal, A
    BLOOD, 1996, 88 (10) : 3800 - 3800
  • [30] Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed acute promyelocytic leukaemia
    Au, WY
    Lie, AKW
    Chim, CS
    Liang, R
    Ma, SK
    Chan, CH
    Mak, YK
    Chen, YT
    So, CC
    Yeung, YM
    Yip, SF
    Wong, LG
    Chan, JC
    Liu, SY
    Kwong, YL
    ANNALS OF ONCOLOGY, 2003, 14 (05) : 752 - 757
12345